MHLW Panel Gives Thumbs Up for Novartis’ ADM Med Brolucizumab for Approval in as Early as March

Novartis Pharma’s age-related macular degeneration (AMD) med brolucizumab was put forward for approval on January 27 by a key health ministry advisory committee. The drug is expected to gain official approval as early as March. The Pharmaceutical Affairs and Food...read more